Stay updated on Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page.

Latest updates to the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page
- Check4 days agoChange DetectedA general NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe footer revision marker changed from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study record content, removing access to the NCT04345367 trial details and locations. This replaces the prior study information with an error page, affecting how users can view or reference this trial on ClinicalTrials.gov.SummaryDifference18%

- Check39 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, indicating a minor update to the page system or content without changing the study information.SummaryDifference0.0%

- Check54 days agoChange DetectedA new publication citation for the post hoc analysis of abrocitinib in atopic dermatitis was added to the Publications section, and the previous online-ahead-of-print citation was removed, reflecting a newer version of the paper.SummaryDifference0.0%

- Check61 days agoChange DetectedAn addition appears in the study identifiers: '2019 ( U.S. NIH Grant/Contract )', indicating NIH funding for the U.S. portion of the trial.SummaryDifference0.0%

Stay in the know with updates to Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Abrocitinib vs Dupilumab in Adult Atopic Dermatitis Clinical Trial page.